Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 1.94
NBS's Cash to Debt is ranked higher than
60% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. NBS: 1.94 )
NBS' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: 1.94

Equity to Asset 0.48
NBS's Equity to Asset is ranked higher than
62% of the 937 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NBS: 0.48 )
NBS' s 10-Year Equity to Asset Range
Min: -40.98   Max: 0.92
Current: 0.48

-40.98
0.92
F-Score: 4
Z-Score: -2.95
M-Score: -2.48
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -314.69
NBS's Operating margin (%) is ranked higher than
63% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -75.73 vs. NBS: -314.69 )
NBS' s 10-Year Operating margin (%) Range
Min: -10991.67   Max: -27.04
Current: -314.69

-10991.67
-27.04
Net-margin (%) -333.29
NBS's Net-margin (%) is ranked higher than
63% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -78.15 vs. NBS: -333.29 )
NBS' s 10-Year Net-margin (%) Range
Min: -13154.35   Max: -33.38
Current: -333.29

-13154.35
-33.38
ROE (%) -93.33
NBS's ROE (%) is ranked higher than
59% of the 1147 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. NBS: -93.33 )
NBS' s 10-Year ROE (%) Range
Min: -578.99   Max: -57.05
Current: -93.33

-578.99
-57.05
ROA (%) -55.94
NBS's ROA (%) is ranked higher than
62% of the 1253 Companies
in the Global Biotechnology industry.

( Industry Median: -27.49 vs. NBS: -55.94 )
NBS' s 10-Year ROA (%) Range
Min: -850.61   Max: -18.34
Current: -55.94

-850.61
-18.34
ROC (Joel Greenblatt) (%) -380.15
NBS's ROC (Joel Greenblatt) (%) is ranked higher than
74% of the 1227 Companies
in the Global Biotechnology industry.

( Industry Median: -437.61 vs. NBS: -380.15 )
NBS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -80050   Max: -46.95
Current: -380.15

-80050
-46.95
Revenue Growth (3Y)(%) -62.40
NBS's Revenue Growth (3Y)(%) is ranked higher than
58% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. NBS: -62.40 )
NBS' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 196.7
Current: -62.4

0
196.7
EBITDA Growth (3Y)(%) -11.10
NBS's EBITDA Growth (3Y)(%) is ranked higher than
72% of the 714 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. NBS: -11.10 )
NBS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -56.8   Max: 14.3
Current: -11.1

-56.8
14.3
EPS Growth (3Y)(%) -25.30
NBS's EPS Growth (3Y)(%) is ranked higher than
66% of the 729 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. NBS: -25.30 )
NBS' s 10-Year EPS Growth (3Y)(%) Range
Min: -52.7   Max: 9.6
Current: -25.3

-52.7
9.6
» NBS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

NBS Guru Trades in

NBS Guru Trades in

Q3 2013

NBS Guru Trades in Q3 2013

Jim Simons 30,037 sh (New)
» More
Q4 2013

NBS Guru Trades in Q4 2013

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NBS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.90
NBS's P/B is ranked higher than
91% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. NBS: 1.90 )
NBS' s 10-Year P/B Range
Min: 0.59   Max: 150
Current: 1.9

0.59
150
P/S 6.20
NBS's P/S is ranked higher than
87% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 28.14 vs. NBS: 6.20 )
NBS' s 10-Year P/S Range
Min: 0.72   Max: 360.71
Current: 6.2

0.72
360.71
EV-to-EBIT -1.92
NBS's EV-to-EBIT is ranked higher than
70% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NBS: -1.92 )
NBS' s 10-Year EV-to-EBIT Range
Min: -8.1   Max: -0.2
Current: -1.92

-8.1
-0.2
Current Ratio 3.49
NBS's Current Ratio is ranked higher than
67% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. NBS: 3.49 )
NBS' s 10-Year Current Ratio Range
Min: 0.01   Max: 12.92
Current: 3.49

0.01
12.92
Quick Ratio 3.31
NBS's Quick Ratio is ranked higher than
68% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. NBS: 3.31 )
NBS' s 10-Year Quick Ratio Range
Min: 0.01   Max: 12.92
Current: 3.31

0.01
12.92

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.40
NBS's Dividend Yield is ranked lower than
82% of the 195 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. NBS: 0.40 )
NBS' s 10-Year Dividend Yield Range
Min: 0.38   Max: 7.04
Current: 0.4

0.38
7.04
Yield on cost (5-Year) 0.40
NBS's Yield on cost (5-Year) is ranked lower than
80% of the 200 Companies
in the Global Biotechnology industry.

( Industry Median: 1.23 vs. NBS: 0.40 )
NBS' s 10-Year Yield on cost (5-Year) Range
Min: 0.38   Max: 7.04
Current: 0.4

0.38
7.04
Share Buyback Rate -58.30
NBS's Share Buyback Rate is ranked higher than
57% of the 855 Companies
in the Global Biotechnology industry.

( Industry Median: -11.00 vs. NBS: -58.30 )
NBS' s 10-Year Share Buyback Rate Range
Min: -14.5   Max: -150.6
Current: -58.3

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.30
NBS's Price/Median PS Value is ranked higher than
98% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. NBS: 0.30 )
NBS' s 10-Year Price/Median PS Value Range
Min: 0.04   Max: 1612.9
Current: 0.3

0.04
1612.9
Earnings Yield (Greenblatt) -50.70
NBS's Earnings Yield (Greenblatt) is ranked higher than
51% of the 1221 Companies
in the Global Biotechnology industry.

( Industry Median: -6.20 vs. NBS: -50.70 )
NBS' s 10-Year Earnings Yield (Greenblatt) Range
Min: -50.7   Max: 0
Current: -50.7

-50.7
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:8NE1.Germany,
Neostem Inc was incorporated under the laws of the State of Delaware on September 18, 1980. It is engaged in cellular therapy industry. The Company develops novel proprietary cell therapy products. It is engaged in therapies that addresses ischemia through its CD34 Cell Program. AMR-001 is its product candidate in the CD34 Cell Program being developed to treat damaged heart muscle following an acute myocardial infarction. The Company competes with various companies like Lonza Group Ltd. and WuXi AppTec. The Company is subject to various governmental regulatory authorities, as well as private accreditation organizations, oversee and monitor the activities of individuals and businesses engaged in the development, manufacture and delivery of health care products and services.
» More Articles for NBS

Headlines

Articles On GuruFocus.com
"New To The Street"Announces Nationwide Broadcast Dec 03 2014 

More From Other Websites
PCT, a NeoStem Company, Presented Lovo® Cell Processing System Data at IBC Life Sciences’... Dec 15 2014
PCT, a NeoStem Company, Presented Lovo(R) Cell Processing System Data at IBC Life Sciences'... Dec 15 2014
NeoStem’s Subsidiary, Progenitor Cell Therapy, Receives AABB Re-Accreditation for its Allendale,... Dec 08 2014
NeoStem's Subsidiary, Progenitor Cell Therapy, Earns AABB Re-Accreditation for Its Allendale, NJ... Dec 08 2014
"New To The Street"Announces Nationwide Broadcast Dec 03 2014
NeoStem, Inc. - "Initial Trial Results of PreSERVE AMI: The Meaningful Clinical Relevance of the... Dec 02 2014
NeoStem and PCT, a NeoStem Company, to Present at Multiple December Conferences Dec 01 2014
NeoStem and PCT, A NeoStem Company, to Present at Multiple December Conferences Dec 01 2014
NeoStem to Host Key Opinion Leader Event Webcast on December 1, 2014 in New York City Nov 26 2014
NeoStem to Host Key Opinion Leader Event Webcast on December 1, 2014 Nov 26 2014
NeoStem CSO Dr. Robert Preti Elected Vice Chairman of the Alliance for Regenerative Medicine Nov 25 2014
NeoStem CSO Dr. Robert Preti Elected Vice Chairman of the Alliance for Regenerative Medicine Nov 25 2014
NeoStem Provides Further Information Regarding the Design of the Phase 2 PreSERVE AMI Clinical Trial Nov 21 2014
NeoStem Provides Further Information Regarding the Design of the Phase 2 PreSERVE AMI Clinical Trial Nov 21 2014
Neostem (NBS): Today's Weak On High Volume Stock Nov 19 2014
NeoStem, Inc. - "Encouraging Findings from PreSERVE AMI" Nov 19 2014
NeoStem, Inc. - "PreSERVE AMI Phase 2 Results" Nov 18 2014
NeoStem (NBS) Stock Plummets Today on Disappointing Cardiac Stem-Cell Therapy Data Nov 18 2014
NeoStem's Stem Cell Therapy Fails Mid-Stage Heart Attack Study Nov 18 2014
NEOSTEM, INC. Files SEC form 8-K, Regulation FD Disclosure Nov 18 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK